Omada Health
Omada Health Inc. is a recognized leader in the digital therapeutics (DTx) sector, known for its strategic focus on innovative programs for chronic disease management. Based in San Francisco, the company has established a significant presence by offering a multi-condition platform that addresses widespread chronic illnesses. Omada’s mission is to provide personalized, accessible digital care that promotes behavior modification for long-term health improvements. Their comprehensive virtual care solution is pivotal in helping members manage conditions such as diabetes, hypertension, and behavioral health challenges. The Omada program leverages smart monitoring devices which seamlessly pair with its application to collect and analyze health data. This information powers personalized support and timely interventions, often incorporating both one-on-one human and digital coaching. By integrating advanced technology and behavioral science, Omada Health is instrumental in improving care plan adherence and driving measurable outcomes, positioning the company as a key force in the shift toward scalable and efficient chronic care management.
Latest Market Research Report on Digital Therapeutics Download PDF Brochure Now
Teladoc Health (Livongo)
Teladoc Health, Inc. is a global leader in comprehensive virtual care, with its robust digital therapeutics capabilities significantly bolstered by the acquisition of Livongo Health. The company is actively involved in expanding the accessibility and reach of DTx solutions through its broad platform. Teladoc’s primary DTx offering focuses on chronic care management, providing members with on-demand support and a combination of human and digital coaching. The Livongo program is designed to help individuals with conditions like diabetes, hypertension, and weight management to adopt healthier habits and adhere to care plans effectively. It utilizes smart monitoring devices to capture real-time health data, which the Livongo app then analyzes to deliver personalized support and immediate interventions. By successfully integrating these DTx components into its larger virtual care framework, Teladoc Health enables a cohesive, patient-centric approach to managing chronic illnesses, making complex care more efficient and widely available across diverse settings.
Akili Interactive Labs
Akili Interactive Labs is a pioneering digital therapeutics company that is fundamentally changing how cognitive disorders are treated by leveraging video game technology. Founded in 2011, Akili is dedicated to creating clinically validated, prescription digital medicines that function as cognitive therapies, tests, and diagnostics. The company’s core technological advance involves developing engaging, software-based programs that target specific neurological pathways to improve cognitive function. A cornerstone of its portfolio is EndeavorRx, the first FDA-cleared video game-based therapeutic specifically indicated to improve attention function in children with ADHD. Akili’s solutions extend beyond pediatric ADHD, with pipeline programs actively addressing conditions such as adult ADHD, depression, and autism. By blending entertainment with rigorous clinical science, Akili provides a unique, non-pharmacological treatment modality that offers a scalable, accessible, and potentially lower-cost alternative to traditional medical procedures for patients with cognitive impairments.
WellDoc
WellDoc is a leading biotechnology digital therapeutics company dedicated to transforming the management of chronic diseases through personalized, software-based interventions. The company has established credibility through multiple FDA clearances and a focus on integrating behavioral science into its product design. WellDoc’s flagship offering, BlueStar, is a prescription standalone software solution for the treatment of adults with Type II diabetes, designed to supplement medication and provide ongoing support. The platform is engineered to offer highly personalized guidance, education, coaching, and self-accountability tools. Furthermore, WellDoc has expanded its therapeutic reach to include conditions like hypertension (BP Star) and heart failure (HF Star), delivering personalized digital solutions for complex care needs. By combining its deep understanding of patient psychology with advanced software technology, WellDoc empowers patients to manage their conditions effectively, minimize manual errors, and ultimately improve long-term clinical outcomes.
Big Health
Big Health is a digital therapeutics company specializing in automated, evidence-based behavioral medicine programs primarily focused on mental health conditions. The company’s strategy is centered on providing accessible, personalized solutions that operate as alternatives or supplements to traditional medication and therapy. Big Health’s two core DTx products are Sleepio and Daylight. Sleepio is a clinically validated software solution that uses cognitive behavioral therapy (CBT) techniques to treat adults with insomnia, proving effective within six to twelve weeks. Daylight is a software solution supported by AI to help adults manage anxiety and worry. By delivering these self-guided, app-based interventions, Big Health effectively scales evidence-based psychological treatment, allowing for a broader and more cost-effective reach. The company is actively focused on expanding its portfolio to address conditions like adolescent depression, reinforcing its commitment to improving global mental health through technology.
MindMaze
MindMaze is an innovative company at the forefront of digital neurotherapeutics, pioneering the development of a Mind/Machine Interface to revolutionize patient care for neurological conditions and brain health. Its core contribution to digital therapeutics involves creating prescription gaming solutions that are used in conjunction with dedicated devices. These solutions are designed to promote neurorehabilitation and recovery of motor and cognitive functions. MindMaze’s product line, which includes MindMotion PRO and MindMotion GO, offers engaging, evidence-based therapy for neurorehabilitation. Additionally, solutions like MindPod Dolphin and Intento PRO (based on self-modulated functional electrical stimulation) are designed to target motor skill recovery and cognitive function in patients with various disorders, including Parkinson’s and autism spectrum disorder. By integrating sophisticated devices with interactive software, MindMaze provides powerful, evidence-based tools that transform the delivery of neurological care and rehabilitation.
Click Therapeutics
Click Therapeutics is a dedicated digital therapeutics company that builds and commercializes a platform of “prescription digital medicines”—mobile software applications used to treat medical conditions. Since its founding in 2012, the company has focused on developing rigorously tested, app-based treatments intended for physician prescription and regulatory clearance. The company’s flagship product, Clickotine, is a phone app designed to assist individuals in quitting smoking, leveraging behavioral healthcare support. The platform creates personalized treatment plans by engaging patients in daily and weekly missions tailored to their specific diagnosis and therapeutic needs. Click Therapeutics is actively advancing its pipeline to address a range of complex medical conditions, including migraine, depression, and chronic lower back pain. By focusing on software as a therapeutic tool and securing significant funding, the company is positioning itself as a leader in delivering scalable, regulated digital treatments.
Kaia Health
Kaia Health is a digital therapeutics company that specializes in providing evidence-based, app-based therapies for musculoskeletal (MSK) conditions and respiratory care. Founded in 2016, the company leverages cutting-edge technology to deliver accessible, personalized treatment programs. Kaia Health is particularly recognized for its AI-enabled motion tracking technology, which is a core component of its MSK pain solution. Using a smartphone camera, the application provides real-time feedback on user exercise performance, ensuring correct form and proper technique. The product portfolio includes Kaia MSK for pain, Kaia Breathe for COPD, and Kaia Balance for fall prevention in older adults. By offering these comprehensive, digitally delivered therapies, Kaia Health effectively scales high-quality physical and respiratory care, demonstrating the potential of AI and motion tracking to democratize access to evidence-based physical therapy.
Sword Health
Sword Health is a leading digital therapeutics company focused on transforming the treatment and prevention of musculoskeletal (MSK) disorders through its AI-driven physical therapy platform. The company provides virtual solutions that are highly personalized, accessible, and designed to manage chronic pain effectively. Sword’s platform delivers digital physical therapy and also includes specialized women’s pelvic health care. A key element of their technology is a proprietary artificial intelligence engine, Phoenix, which analyzes user data to identify members at risk of needing surgery and proactively engages them in preventative interventions. This approach leverages real-time data and conversational AI to tailor the care experience. By providing a comprehensive, remote care model that combines human clinical support with intelligent technology, Sword Health significantly enhances the quality of care for MSK conditions and is rapidly expanding its global footprint in the digital health sector.
Biofourmis
Biofourmis is a global health IT start-up that utilizes artificial intelligence and machine learning to deliver personalized, “digital pharmaceutical” solutions and advanced remote care services. The company’s core platform is a sophisticated care delivery system designed to interpret and analyze physiological data collected from a variety of clinically validated monitoring devices. Biofourmis applies its advanced analytics engine to “learn” a patient’s individual baseline, allowing it to support clinical judgment and deliver a wide spectrum of care, including chronic disease management and hospital-at-home programs. The system uses customizable care pathways and significantly reduces false positive alerts, enhancing clinical efficiency. By seamlessly integrating AI, data analytics, and connected devices, Biofourmis provides the critical technological infrastructure for next-generation personalized care, enabling continuous monitoring and proactive, data-driven disease management.
Latest Market Research Report on Digital Therapeutics Download PDF Brochure Now